Canada
· Delayed Price · Currency is CAD NervGen Pharma Company Description
NervGen Pharma Corp., a clinical-stage biotech company together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage.
The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, in a preclinical model of ischemic stroke and confirmatory SCI study.
It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage.
The company was incorporated in 2017 and is based in Vancouver, Canada.
| Country | Canada |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Michael Kelly |
Contact Details
Address: 112-970 Burrard Street Vancouver, British Columbia V6Z 2R4 Canada | |
| Phone | 778 731 1711 |
| Website | nervgen.com |
Stock Details
| Ticker Symbol | NGEN |
| Exchange | TSX Venture Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA64082X2032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael P. Kelly | Chief Executive Officer, President and Director |
| William Joseph Radvak BASc | Co-Founder and Advisor |
| Dr. Harold Martin Punnett D.M.D. | Co-Founder and Independent Director |
| William J. Adams C.A., CPA, CA, CPA | Chief Financial Officer and Corporate Secretary |
| Dr. Daniel D. Mikol M.D., Ph.D. | Chief Medical Officer |
| Brian McAlister | Co-Founder and Advisor |
| Dr. Charles V. Olson D.Sc. | Senior Vice President of Technical Operations |
| Kevin M. Rooney | Senior Vice President of Corporate Development and Strategy |
| Elizabeth Eberhardt B.Sc. | Senior Vice President of Program Management |